LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

• Status: Completed
• Trial end date: 2017-07-06
• Target enrollment: 0
• Participant gender: All

Summary

A study of LEO 32731 in the treatment of psoriasis vulgaris

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma

Criteria

Inclusion Criteria:

• Signed and dated informed consent

• Aged between 18 years and 65.

• Males or females of non-childbearing potential.

• Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis

• Have moderate to severe psoriasis vulgaris

• Candidates of systemic anti-psoriatic treatment and/or phototherapy

Exclusion Criteria:

• Subjects with therapy resistant psoriasis

• Previously exposed to apremilast

• Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris

• Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris